167 related articles for article (PubMed ID: 27589204)
41. Germline variants screening of MLH1, MSH2, MSH6 and PMS2 genes in 64 Algerian Lynch syndrome families: The first nationwide study.
Boumehdi AL; Cherbal F; Khider F; Oukkal M; Mahfouf H; Zebboudj F; Maaoui M
Ann Hum Genet; 2022 Nov; 86(6):328-352. PubMed ID: 36073783
[TBL] [Abstract][Full Text] [Related]
42. Refining the role of PMS2 in Lynch syndrome: germline mutational analysis improved by comprehensive assessment of variants.
Borràs E; Pineda M; Cadiñanos J; Del Valle J; Brieger A; Hinrichsen I; Cabanillas R; Navarro M; Brunet J; Sanjuan X; Musulen E; van der Klift H; Lázaro C; Plotz G; Blanco I; Capellá G
J Med Genet; 2013 Aug; 50(8):552-63. PubMed ID: 23709753
[TBL] [Abstract][Full Text] [Related]
43. Prevalence and molecular characteristics of DNA mismatch repair deficient endometrial cancer in a Japanese hospital-based population.
Yamamoto A; Yamaguchi T; Suzuki O; Ito T; Chika N; Kamae N; Tamaru JI; Nagai T; Seki H; Arai T; Tachikawa T; Akagi K; Eguchi H; Okazaki Y; Ishida H
Jpn J Clin Oncol; 2021 Jan; 51(1):60-69. PubMed ID: 32844218
[TBL] [Abstract][Full Text] [Related]
44. Next generation sequencing to decipher concurrent loss of PMS2 and MSH6 in colorectal cancer.
Moreno E; Rosa-Rosa JM; Caniego-Casas T; Ruz-Caracuel I; Perna C; Guillén C; Palacios J
Diagn Pathol; 2020 Jul; 15(1):84. PubMed ID: 32664968
[TBL] [Abstract][Full Text] [Related]
45. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
Hall G; Clarkson A; Shi A; Langford E; Leung H; Eckstein RP; Gill AJ
Pathology; 2010; 42(5):409-13. PubMed ID: 20632815
[TBL] [Abstract][Full Text] [Related]
46. Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome.
Guindalini RS; Win AK; Gulden C; Lindor NM; Newcomb PA; Haile RW; Raymond V; Stoffel E; Hall M; Llor X; Ukaegbu CI; Solomon I; Weitzel J; Kalady M; Blanco A; Terdiman J; Shuttlesworth GA; Lynch PM; Hampel H; Lynch HT; Jenkins MA; Olopade OI; Kupfer SS
Gastroenterology; 2015 Nov; 149(6):1446-53. PubMed ID: 26248088
[TBL] [Abstract][Full Text] [Related]
47. [Difference analysis of somatic mutations between deficient mismatch repair and proficient mismatch repair gene related with colorectal cancer].
Tang XJ; Yang MY; Zhu LZ; Xu D; Yuan Y
Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1088-1093. PubMed ID: 34695900
[No Abstract] [Full Text] [Related]
48. Germline mutation and protein expression analysis of mismatch repair genes MSH6 and PMS2 in Malaysian Lynch syndrome patients.
Zahary MN; Kaur G; Hassan MR; Sidek AS; Singh H; Yeh LY; Ankathil R
Int J Colorectal Dis; 2014 Feb; 29(2):261-2. PubMed ID: 24072394
[No Abstract] [Full Text] [Related]
49. Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation.
McCarthy AJ; Capo-Chichi JM; Spence T; Grenier S; Stockley T; Kamel-Reid S; Serra S; Sabatini P; Chetty R
J Pathol Clin Res; 2019 Apr; 5(2):115-129. PubMed ID: 30387329
[TBL] [Abstract][Full Text] [Related]
50. PMS2 involvement in patients suspected of Lynch syndrome.
Niessen RC; Kleibeuker JH; Westers H; Jager PO; Rozeveld D; Bos KK; Boersma-van Ek W; Hollema H; Sijmons RH; Hofstra RM
Genes Chromosomes Cancer; 2009 Apr; 48(4):322-9. PubMed ID: 19132747
[TBL] [Abstract][Full Text] [Related]
51. Prevalence and molecular characteristics of defective mismatch repair epithelial ovarian cancer in a Japanese hospital-based population.
Tajima Y; Eguchi H; Chika N; Nagai T; Dechamethakun S; Kumamoto K; Tachikawa T; Akagi K; Tamaru JI; Seki H; Okazaki Y; Ishida H
Jpn J Clin Oncol; 2018 Aug; 48(8):728-735. PubMed ID: 29889250
[TBL] [Abstract][Full Text] [Related]
52. DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer.
Ricker CN; Hanna DL; Peng C; Nguyen NT; Stern MC; Schmit SL; Idos GE; Patel R; Tsai S; Ramirez V; Lin S; Shamasunadara V; Barzi A; Lenz HJ; Figueiredo JC
Cancer; 2017 Oct; 123(19):3732-3743. PubMed ID: 28640387
[TBL] [Abstract][Full Text] [Related]
53. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening.
Urakami S; Inoshita N; Oka S; Miyama Y; Nomura S; Arai M; Sakaguchi K; Kurosawa K; Okaneya T
Int J Urol; 2018 Feb; 25(2):151-156. PubMed ID: 29164703
[TBL] [Abstract][Full Text] [Related]
54. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.
Mills AM; Liou S; Ford JM; Berek JS; Pai RK; Longacre TA
Am J Surg Pathol; 2014 Nov; 38(11):1501-9. PubMed ID: 25229768
[TBL] [Abstract][Full Text] [Related]
55. Clinical analysis of PMS2: mutation detection and avoidance of pseudogenes.
Vaughn CP; Robles J; Swensen JJ; Miller CE; Lyon E; Mao R; Bayrak-Toydemir P; Samowitz WS
Hum Mutat; 2010 May; 31(5):588-93. PubMed ID: 20205264
[TBL] [Abstract][Full Text] [Related]
56. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
57. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
[TBL] [Abstract][Full Text] [Related]
58. Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome: a new molecular, clinicopathological feature.
Zeinalian M; Emami MH; Salehi R; Naimi A; Kazemi M; Hashemzadeh-Chaleshtori M
J Gastrointest Cancer; 2015 Jun; 46(2):118-25. PubMed ID: 25722176
[TBL] [Abstract][Full Text] [Related]
59. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel.
Shia J; Tang LH; Vakiani E; Guillem JG; Stadler ZK; Soslow RA; Katabi N; Weiser MR; Paty PB; Temple LK; Nash GM; Wong WD; Offit K; Klimstra DS
Am J Surg Pathol; 2009 Nov; 33(11):1639-45. PubMed ID: 19701074
[TBL] [Abstract][Full Text] [Related]
60. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
